Diagnosis and Management of CKD with Hypertension and Elevated Free Kappa Light Chains

Diagnostic Evaluation

The American Society of Nephrology recommends obtaining serum free light chain assay with kappa/lambda ratio to distinguish monoclonal from polyclonal elevation in patients with CKD 1
The International Myeloma Society suggests ordering serum and urine protein electrophoresis with immunofixation to detect monoclonal immunoglobulin in patients with CKD and elevated free kappa light chains 1
The European Renal Association recommends performing bone marrow biopsy if kappa/lambda ratio is abnormal to exclude multiple myeloma or MGRS 1

The American Heart Association recommends targeting systolic BP <130 mmHg (or <120 mmHg if tolerated) in patients with CKD and hypertension 4
The European Society of Cardiology suggests initiating ACE inhibitor or ARB as first-line therapy in patients with CKD and hypertension, with a strong recommendation (1B) for severely increased albuminuria (≥300 mg/g) and a weaker recommendation (2C) for moderately increased albuminuria (30-299 mg/g) 2, 3, 6, 7
The American Diabetes Association recommends adding long-acting dihydropyridine calcium channel blocker as second agent if BP remains uncontrolled 2, 7

The European Society of Cardiology recommends obtaining 12-lead ECG to assess for left ventricular hypertrophy and arrhythmias in patients with CKD and elevated beta-2 microglobulin 4, 5
The American Heart Association suggests considering echocardiography to evaluate for hypertension-mediated organ damage, particularly if ECG is abnormal or cardiac symptoms are present 4, 5

The National Kidney Foundation recommends measuring serum creatinine, eGFR, and urine albumin-to-creatinine ratio at least annually in patients with moderate-to-severe CKD 4, 5
The American Society of Nephrology suggests expecting modest eGFR decline with intensive BP control, and continuing therapy if tolerated as cardiovascular benefits outweigh this decline 7

The American Society of Nephrology recommends referring to nephrologist if eGFR <30 mL/min/1.73 m², or if there is uncertainty about etiology of kidney disease, or if there is rapidly progressing kidney disease 6
The International Myeloma Society suggests referring to nephrologist if confirmed monoclonal immunoglobulin-associated renal disease 1